Supernus Pharmaceuticals Stock Buy Hold or Sell Recommendation
| SUPN Stock | USD 36.57 0.42 1.14% |
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding Supernus Pharmaceuticals is 'Strong Hold'. The recommendation algorithm takes into account all of Supernus Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out Supernus Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Supernus and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Supernus |
Execute Supernus Pharmaceuticals Buy or Sell Advice
The Supernus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Supernus Pharmaceuticals. Macroaxis does not own or have any residual interests in Supernus Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Supernus Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Supernus Pharmaceuticals Trading Alerts and Improvement Suggestions
| Supernus Pharmaceuticals currently holds 41.53 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Supernus Pharmaceuticals has a current ratio of 0.83, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Supernus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Over 95.0% of Supernus Pharmaceuticals shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference |
Supernus Pharmaceuticals Returns Distribution Density
The distribution of Supernus Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Supernus Pharmaceuticals' future price movements. The chart of the probability distribution of Supernus Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Supernus Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Supernus Pharmaceuticals returns is essential to provide solid investment advice for Supernus Pharmaceuticals.
| Mean Return | 0.10 | Value At Risk | -2.71 | Potential Upside | 2.77 | Standard Deviation | 2.06 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Supernus Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Supernus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Supernus Pharmaceuticals, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Supernus Pharmaceuticals back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Pacer Advisors, Inc. | 2024-06-30 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.2 M | Aristotle Capital Boston, Llc | 2024-06-30 | 1.2 M | American Century Companies Inc | 2024-09-30 | 1 M | Victory Capital Management Inc. | 2024-09-30 | 742.9 K | Charles Schwab Investment Management Inc | 2024-09-30 | 712.4 K | Ashford Capital Management Inc | 2024-06-30 | 711.9 K | Northern Trust Corp | 2024-09-30 | 606.3 K | Blackrock Inc | 2024-06-30 | 10.4 M | Vanguard Group Inc | 2024-09-30 | 6.1 M |
Supernus Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (969K) | (10.1M) | (14.6M) | (17.9M) | 6.1M | 6.4M | |
| Change In Cash | (10.9M) | 107.3M | (85.2M) | (110.3M) | (18.1M) | (17.2M) | |
| Free Cash Flow | 140.4M | 135.0M | 125.1M | 116.4M | 110.5M | 116.1M | |
| Depreciation | 6.7M | 18.1M | 32.6M | 85.5M | 84.9M | 89.1M | |
| Capital Expenditures | 2.7M | 3.4M | 2.0M | 412K | 551K | 523.5K | |
| Net Income | 113.1M | 127.0M | 53.4M | 60.7M | 1.3M | 1.3M | |
| End Period Cash Flow | 181.4M | 288.6M | 203.4M | 93.1M | 75.1M | 97.3M | |
| Other Non Cash Items | 13.8M | 12.7M | 24.6M | 3.6M | 33.0M | 34.7M | |
| Investments | (156.5M) | 267.5M | 218.9M | (216.3M) | 285.9M | 300.2M | |
| Change Receivables | 15.8M | (34.6M) | 3.9M | (16.4M) | (14.7M) | (15.5M) | |
| Change To Netincome | 9.0M | 16.1M | 19.6M | (10.5M) | (12.1M) | (11.5M) |
Supernus Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Supernus Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Supernus Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Supernus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | 1.09 | |
σ | Overall volatility | 2.08 | |
Ir | Information ratio | -0.02 |
Supernus Pharmaceuticals Volatility Alert
Supernus Pharmaceuticals currently demonstrates below-average downside deviation. It has Information Ratio of -0.02 and Jensen Alpha of -0.05. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Supernus Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Supernus Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Supernus Pharmaceuticals Fundamentals Vs Peers
Comparing Supernus Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Supernus Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Supernus Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Supernus Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Supernus Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Supernus Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Supernus Pharmaceuticals to competition |
| Fundamentals | Supernus Pharmaceuticals | Peer Average |
| Return On Equity | 0.0622 | -0.31 |
| Return On Asset | 0.0289 | -0.14 |
| Profit Margin | 0.09 % | (1.27) % |
| Operating Margin | 0.16 % | (5.51) % |
| Current Valuation | 1.65 B | 16.62 B |
| Shares Outstanding | 55.22 M | 571.82 M |
| Shares Owned By Insiders | 5.01 % | 10.09 % |
| Shares Owned By Institutions | 94.99 % | 39.21 % |
| Number Of Shares Shorted | 6.52 M | 4.71 M |
| Price To Earning | 15.25 X | 28.72 X |
| Price To Book | 2.00 X | 9.51 X |
| Price To Sales | 3.13 X | 11.42 X |
| Revenue | 607.52 M | 9.43 B |
| Gross Profit | 580.02 M | 27.38 B |
| EBITDA | 90.04 M | 3.9 B |
| Net Income | 1.32 M | 570.98 M |
| Cash And Equivalents | 360.79 M | 2.7 B |
| Cash Per Share | 6.74 X | 5.01 X |
| Total Debt | 41.53 M | 5.32 B |
| Debt To Equity | 0.53 % | 48.70 % |
| Current Ratio | 0.85 X | 2.16 X |
| Book Value Per Share | 18.24 X | 1.93 K |
| Cash Flow From Operations | 111.08 M | 971.22 M |
| Short Ratio | 16.46 X | 4.00 X |
| Earnings Per Share | 1.07 X | 3.12 X |
| Price To Earnings To Growth | 1.47 X | 4.89 X |
| Target Price | 39.25 | |
| Number Of Employees | 652 | 18.84 K |
| Beta | 0.87 | -0.15 |
| Market Capitalization | 2.04 B | 19.03 B |
| Total Asset | 1.28 B | 29.47 B |
| Retained Earnings | 482.56 M | 9.33 B |
| Working Capital | 202.92 M | 1.48 B |
Note: Disposition of 20000 shares by Newhall Charles W Iii of Supernus Pharmaceuticals at 9.13 subject to Rule 16b-3 [view details]
Supernus Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Supernus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Supernus Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Supernus Pharmaceuticals? Buying financial instruments such as Supernus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Supernus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Industrials ETFs Thematic Idea Now
Industrials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Supernus Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.